ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genentech Teams With Arvinas

by Lisa M. Jarvis
October 12, 2015 | APPEARED IN VOLUME 93, ISSUE 40

Genentech and Arvinas will work together to develop small molecules that invoke protein degradation and disposal. The pact, which includes an undisclosed up-front payment, could be worth up to $300 million in milestones for privately held Arvinas, which was spun out of the labs of Yale University chemist Craig Crews. Whereas conventional drugs work by blocking the activity of a protein, Arvinas is using bifunctional small molecules called proteolysis-targeting chimeras to “tag” certain proteins for breakdown by the ubiquitin-proteasome system.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment